Anglo-German firm Cellzome says it has formed a second strategic alliance with UK drug giant GlaxoSmithKline providing the latter with exclusive access to Cellzome's proprietary Episphere technology in the emerging field of epigenetics as applied to immune-inflammatory disease. Epigenetic mechanisms play a key role in controlling immune cell differentiation and inflammatory gene expression during an excessive inflammatory response.
Financial terms of the deal mean that Cellzome will receive an upfront payment of 33 million euros ($44.9 million), comprising technology access fees and the purchase of equity. In addition, Cellzome is eligible for milestone payments and tiered royalties for each program. Milestones under this collaboration could reach over 475 million euros if all programmes under the alliance are successfully developed and commercialised.
The deal follows on from one signed between the companies in September 2008 focusing on Cellzome's Kinobeads technology that saw the Cambridge-headquartered firm receive upfront payments of £14.4 million ($21.7 million) in both cash and equity and provision for up to £118 million per program in potential development, regulatory and commercial milestones.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze